An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
The goal of this clinical research study is to learn if pacritinib can help control myelofibrosis and to find a recommended dose. The safety of this drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 01/17/2018
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: